Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma
- 1 November 1996
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 57 (5) , 335-340
- https://doi.org/10.1111/j.1600-0609.1996.tb01390.x
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Clinical Significance of Serial Measurement of the Serum Levels of Soluble Interleukin-2 Receptor and Soluble CD8 in Malignant LymphomaLeukemia & Lymphoma, 1995
- Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignanciesCancer, 1994
- Interleukin-6 Levels in the Plasma of Patients with LymphomaLeukemia & Lymphoma, 1992
- Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphomaBritish Journal of Cancer, 1992
- Serum Soluble Interleukin-2 Receptor Levels are Associated with Clinical Disease Status and Histopathological Grade in Non-Hodgkin's Lymphoma and Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 1992
- The identification of discrete prognostic groups in low grade non-Hodgkin's lymphomaAnnals of Oncology, 1991
- Fludarabine phosphate for the treatment of low grade lymphoid malignancyBritish Journal of Cancer, 1991
- Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parametersAnnals of Hematology, 1991
- Prognostic significance of flow cytometry studies in B-cell non-hodgkin lymphomaHematological Oncology, 1990
- Ki67 and 4F2 antigen expression as well as dna synthesis predict survival at relapse/tumour progression in low‐grade B‐cell lymphomaInternational Journal of Cancer, 1989